Samer Khaled MD

Hematologic Oncology

Associate Professor

1400 S Orange AveOrlando, FL 32806
Phone+1 321-843-2810
Fax+1 321-843-6330

Dr. Khaled is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khaled's full profile Already have an account?

Education & Training

Brooklyn Hospital CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Brooklyn Hospital CenterResidency, Internal Medicine, 2002 - 2006
Cairo University School of MedicineClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2009 - 2027
FL State Medical License 2005 - 2027
TN State Medical License 2025 - 2027
NY State Medical License 2008 - 2016
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Sunrise Acute Care, Allscripts, 2013-2017
CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Ambulatory Care EHR, Allscripts, 2013-2017
CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2013-2017

Clinical Trials

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
COMPLETED
PHASE2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia Start of enrollment: 2014 Feb 10
ACTIVE_NOT_RECRUITING
PHASE2
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
COMPLETED
PHASE2

Publications & Presentations

PubMed

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.
Tamer Othman, Vaibhav Agrawal, Joo Y Song, Zhaohui Gu, Paul Koller
American Journal of Hematology. 2026-07-23
Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Le Xuan Truong Nguyen, Bin Zhang, Dinh Hoa Hoang, Dandan Zhao, Huafeng Wang
Leukemia. 2025-07-01
Correction: TET2 deficiency promotes MDS-associated leukemogenesis.
Feiteng Huang, Jie Sun, Wei Chen, Lei Zhang, Xin He
Blood Cancer Journal. 2023-11-28

Abstracts/Posters

Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid L...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)_Mutated Relapsed/Refractory Acute Myeloid Leukem...
Samer K. Khaled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial ResultsMarch 1st, 2021
City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
City of Hope Doctors Present New Research on CAR T Cell Therapy, Bone Marrow Transplants and Other Treatments for Blood CancersNovember 19th, 2018